Abstract We evaluated the relationship of systolic blood pressure, diastolic blood pressure, pulse pressure, and treatment with antihypertensives with knee osteoarthritis incidence in a US cohort. We performed a longitudinal study (2004)(2005)(2006)(2007)(2008)(2009)(2010) nested within the Osteoarthritis Initiative Study including only individuals without knee osteoarthritis at baseline. Systolic blood pressure, diastolic blood pressure, and pulse pressure were assessed at baseline, 12-, 24-, and 36-month visits. Knee radiographs at baseline, 12-, 24-, 36-and 48-month visits defined radiographic osteoarthritis, Kellgren and Lawrence grade ≥2. We performed logistic regression, adjusting for age, sex, body mass index, NSAID use, number of antihypertensive medications, diabetic medications, and cholesterol medications. One thousand nine hundred and thirty people (6040 observations) were included. Annual incidence rates of radiographic osteoarthritis by systolic blood pressure quartiles (lowest to highest) were 2.1, 3.4, 3.7, and 3.7%. Fully adjusted odds ratios of incident radiographic osteoarthritis (OA) for the 2nd-4th quartiles were 1.6, 1.7, and 1.6 relative to the lowest quartile (p for trend = 0.03). Pulse pressure results were similar. There was no association with diastolic blood pressure. Compared to those not taking any antihypertensive medications, those taking ≥3 had decreased odds (0.4, 0.1-1.0) of developing incident OA. In a US cohort, higher systolic blood pressure and pulse pressure are associated with increased incidence of radiographic knee osteoarthritis while treatment with ≥3 antihypertensive medications was associated with reduced incidence. These findings suggest a new and promising avenue for research on disease modification in knee osteoarthritis.
Introduction
Osteoarthritis (OA) is the most common form of arthritis, and a major public health problem, with at least 30 million adults in the USA with clinical OA [1] . Healthcare expenditures are estimated at $189 billion annually in the USA [2] . Further, OA is the most frequent cause of dependency in lower limb tasks, especially in the elderly [3] , and accounts for 68 million work loss days per year in the USA and more than 5% of the annual retirement rate [4] . It is also the most frequent reason for arthroplasty, of which more than 700,000 are performed annually in the USA [5] , equivalent to 2.2 per 1000 persons [6] , approximately triple the rates seen in Scandinavian countries where the rates are 0.7 per 1000 persons [7] [8] [9] , which is still a very common procedure.
The burden of knee OA is particularly heavy because only a limited number of effective treatments have been identified, including physical therapy [10] , weight loss [11] , nonsteroidal antiinflammatory drugs (NSAIDs) [12] , and arthroplasty [13] . Because the natural history of knee OA is long, much of the emphasis of randomized controlled trials has been on those with established disease and persistent symptoms. However, the opportunity to intervene may occur early in disease, supporting attempts to identify risk factors for incident OA.
A study from Japan, the Research on Osteoarthritis and Osteoporosis Against Disability (ROAD) Study, reported an association between the accumulation of metabolic syndrome factors and incident knee OA [14] . Its main focus was evaluating the relationship of metabolic syndrome as a whole, not the individual factors, as it related to incident knee OA. Hypertension was the most common factor observed occurring in 67% of the cohort. In univariate analyses, systolic but not diastolic blood pressure was higher in those who developed knee OA compared to those who did not. To validate these findings, and because results from a Japanese cohort may not be generalizable to other populations, it is important to replicate the study in a different cohort, adjusting for potential confounders. Further, these findings raise the hypothesis that an increase in pulse pressure, defined as systolic blood pressure minus diastolic blood pressure, and generally regarded as an indicator of arterial stiffness [15] , may be a risk factor for incident knee OA. To our knowledge, the relationship between pulse pressure and knee OA has never been evaluated. We also expected that treatment of elevated systolic pressure and pulse pressure would be associated with a reduced incidence of knee OA.
Therefore, the objectives of our study were to evaluate whether higher systolic blood pressure, diastolic blood pressure, and pulse pressure and treatment with antihypertensives were associated with incident radiographic knee OA in a US cohort.
Materials and methods

Study design
This is a longitudinal study (2004) (2005) (2006) (2007) (2008) (2009) (2010) nested within the Osteoarthritis Initiative (OAI), a publicly available multicenter observational study. Full details of the study design of the OAI are available online at https://oai.epi-ucsf.org/ datarelease/docs/StudyDesignProtocol.pdf
In this study, we included all participants of the OAI who had at least a baseline clinical visit and a 12-month follow-up visit where blood pressure assessments and osteoarthritis assessments were available. Because this was a study of incident knee OA, only those who did not have OA in either knee at baseline were included in this study. This study was approved by the Institutional Review Board at Baylor College of Medicine (K23 H-30423). Each participant provided written informed consent.
Systemic blood pressure measurements
Participants were asked to refrain from drinking any caffeine, eating, doing heavy physical activity, smoking, or ingesting alcohol for 30 min prior to the blood pressure measurement. Additionally, in the clinic, they were asked to sit upright comfortably in a chair with back supported and rest for 5 min with legs and ankles uncrossed and their feet flat on the floor prior to the blood pressure assessment. A maximal inflation level was determined by adding 30 mm of Hg to the palpated systolic blood pressure. Subsequently, a manual systolic and diastolic blood pressure was measured using conventional mercury sphygmomanometers, stethoscopes, and the appropriate size blood pressure cuffs. Pulse pressure was defined as systolic blood pressure minus diastolic blood pressure. Blood pressure measurements were assessed at OAI baseline, 12-, 24-, and 36-month visits. These data are publicly available on the OAI website (http://oai.epi-ucsf.org/datarelease/) under filenames AllClinical00_SAS (version 0.2.2), AllClinical01_SAS (version 1.2.1), AllClinical03_SAS (version 3.2.1), and AllClinical05_SAS (version 5.2.1).
Physical activity assessment
The Physical Activity Scale for the Elderly (PASE) [16] reflecting amount and level of physical activity over the prior 7 days was assessed at OAI baseline, 12-, 24-, and 36-month visits. These data were available from the same files used to obtain blood pressure data.
Medication data
Detailed medication inventory data for prescription medicines taken during the 30 days prior to a clinic visit was obtained at OAI baseline, 12-, 24-, and 36-month visits. Each medication was mapped to ingredients through use of a medicationcoding dictionary adapted from the Women's Health and Aging Study [17] , and these ingredients were then hierarchically organized and numerically coded using the Iowa Drug Information Service database of ingredients [18] . These data are publicly available on the OAI website (http://oai.epi-ucsf. Antihypertensive medications GL individually reviewed medication ingredients to identify the following groups of antihypertensive medications: calcium channel blocker, beta blocker, angiotensin converter enzyme inhibitor, angiotensin receptor II antagonist, alpha antagonist, diuretic, or miscellaneous antihypertensive medication (i.e., hydralazine, minoxidil, and nitrates).
Nonsteroidal antiinflammatory drugs Participants were asked whether they took either over-the-counter or prescription NSAIDs on most days of the month in the last month. GL also individually reviewed medication ingredients to identify traditional NSAIDs and Cox-2 inhibitors. If participants reported an NSAID (including diclofenac, etodolac, ibuprofen, indomethacin, ketorolac, ketoprofen, meloxicam, nabumetone, naproxen, piroxicam, rofecoxib, or celecoxib) in their medication inventory or answered affirmative to the dichotomous questions about NSAIDs, they were categorized as being exposed to an NSAID.
Diabetic medications GL individually reviewed medication ingredients to identify all of the following diabetic medications: glipizide, glyburide, glimepiride, glibornuride, repaglinide, nateglinide, metformin, rosiglitazone, pioglitazone, and insulin. If participants were on any of these medications, they were categorized as taking a diabetic medication. Because serum glucose levels were not available for these participants, this was the best alternative method available for assessing diabetes status at the baseline, 12-, 24-and 36-month follow-up visits.
Cholesterol medications Using the medication inventory, GL identified the following medications as lipid lowering medications: atorvastatin, fluvastatin, lovastatin, rosuvastatin, simvastatin, niacin, colesevelam, colestipol, cholestyramine, fenofibrate, and gemfibrozil. If participants were on any of these medications, they were categorized as taking cholesterol medications. Classification of hyperlipidemia status based on medication administration was our best effort to appropriately classify people's hyperlipidemia status since we did not have information on fasting lipid panels at any study visit.
Knee radiographs
Weight-bearing, fixed-flexion, posterior-anterior radiographs of bilateral knees were obtained at the OAI baseline, 12-, 24-, 36-, and 48-month visits. Central readers [19] scored these for overall radiographic severity using Kellgren-Lawrence grades (0-4) using the Osteoarthritis Research Society International Atlas [20] . These data are publicly available on the OAI website (http://oai.epi-ucsf.org/datarelease/), filename kXR_ SQ_BU06_SAS (version 6.3)). The reliability for these readings (read-reread) was substantial [21] (weighted kappa [intra-rater reliability] = 0.71 [95% confidence interval [CI] 0. 55-0.87]) [22] . Those knees with a Kellgren and Lawrence grade ≥2 were defined as having radiographic OA (ROA). If a knee had a total joint replacement, it was assigned as having ROA.
Outcome definition
Incident ROA was a person-based definition reflecting the development of ROA in either knee 12 months after the exposure assessment.
Covariates
Sex was based on self-report from the OAI baseline visit. Date of birth from OAI baseline visit was used to calculate participant age at each OAI visit. Body mass index (BMI) at each visit was calculated as weight (measured at each visit) divided by most recently measured height squared (kg/m 2 ) (measured at every other OAI visit).
Statistical analysis
We evaluated the influence of systolic blood pressure, diastolic blood pressure, and pulse pressure quartiles including time points at baseline, months 12, 24, and 36 on the development of incident ROA in at least one knee 12 months after blood pressure assessments, meaning months 12, 24, 36, and 48. Each time point was treated as a separate observation (e.g., we evaluated whether a participant's quartile of systolic blood pressure at baseline was predictive of incident OA at the 12-month visit. Then, if the participant did not develop OA, we evaluated whether his/her quartile of systolic blood pressure at 12 months was predictive of incident OA at the 24 month visit, etc.). We performed repeated measures longitudinal analyses using generalized estimating equations to adjust for correlations across visits within the same person over time [23] . Once participants developed incident ROA, they were censored from the analyses. Each participant could contribute up to four observation periods. The Cochran-Armitage trend test was used to assess for statistically significant trends [24, 25] . We performed the analyses unadjusted and then adjusted for potential confounders including age, sex, body mass index, PASE, NSAIDs use, number of antihypertensive medications (0, 1, 2, or ≥3), diabetic medication use, and cholesterol medication use at the baseline, 12-, 24-, and 36-month visits. Participants missing either radiographic reading or blood pressure reading were excluded from the analyses at that particular visit.
Because systolic blood pressure and pulse pressure quartiles 2-4 did not exhibit a typical dose response relationship, we performed post-hoc logistic regression analyses collapsing those quartiles into one group.
All analyses were performed using SAS version 9.4. pvalues <0.05 were considered statistically significant.
Results
In total, 1930 participants contributed 6040 observations. A flow diagram for the cohort is included in Fig. 1 . Mean age was 59.2 years (9.1), mean body mass index was 27.2 kg/m 2 (4.5), and 42% of the group were male.
Number of antihypertensive medications, diabetic medication use, and cholesterol medication use were all associated with increased systolic blood pressure and pulse pressure ( Table 1) .
There was a statistically significant increased incidence of ROA with increased systolic blood pressure and pulse pressure quartiles (Tables 2 and 3 ), but not with diastolic blood pressure ( Table 4 ). The associations between both systolic blood pressure and pulse pressure and incident knee ROA persisted after adjusting for age, sex, body mass index, PASE, NSAID use, number of antihypertensive medications, diabetic medications, and cholesterol medications (Tables 2  and 3 ). Post-hoc analyses comparing systolic blood pressure quartiles 2-4 (ROA incidence of 3.6%) against quartile 1 (2.1%) resulted in unadjusted and adjusted odds ratios (ORs) of 1.7 (95% CI 1.2-2.5) and 1.6 (95% CI 1.1-2.4), respectively. Comparing pulse pressure quartiles 2-4 (ROA incidence 3.6%) against quartile 1 (2.2%), unadjusted and adjusted ORs were 1.7 (95% CI 1.2-2.4) and 1.6 (95% CI 1.1-2.4), respectively.
In the fully adjusted models, greater number of antihypertensive medications was associated with a lower risk of incident ROA. Participants taking ≥3 antihypertensive medications had decreased odds (0.4, 0.1-1.0) of developing incident ROA compared to those not taking any antihypertensive medications. However, adding antihypertensive medications into 
Discussion
We have demonstrated that higher systolic blood pressure and pulse pressure, but not diastolic blood pressure, were associated with increased incidence of ROA in a US-based cohort, the OAI. Further, use of three or more antihypertensive agents was associated with a lower incidence of ROA. Prior uncontrolled studies have described that hypertension is common among people with OA [26, 27] . The Japanese ROAD study [14] presented univariate unadjusted analysis identifying an association between incident ROA and systolic but not diastolic blood pressure. After adjusting for potential confounders including physical activity and NSAID use, with a known side effect of hypertension [28 ,29] , as well as diabetes and cholesterol medications, our study has replicated this relationship, and we are the first to show an association of pulse pressure with incident ROA. Systolic and diastolic blood pressures are the maximal and minimal pressures in the aorta during the cardiac cycle. Pulse pressure is the difference between the two. We found elevated systolic blood pressure and pulse pressure but not diastolic blood pressure to associate with incident knee ROA. A pulse pressure of greater than 38 conferred a 70% increased odds for incident ROA. Similarly, a systolic blood pressure of greater than 111 conferred a 70% increased odds for incident ROA. Many people on the largest number of medications had substantially elevated systolic blood pressure and pulse pressures, consistent with real world management of hypertension [30] . Interestingly, those taking ≥3 antihypertensive medications had decreased odds (0.4, 0.1-1.0) of developing incident OA compared to those not taking any antihypertensive medications, suggesting that treatment of hypertension may reduce the incidence of knee OA.
The pattern of having an elevated systolic blood pressure and pulse pressure without an elevated diastolic blood pressure is consistent with isolated systolic hypertension, though the specific definition is a systolic blood pressure >160 when the diastolic blood pressure is <95 [31] . This is a phenomenon attributed to arterial stiffness [32] , aortic stiffness, and endothelial dysfunction [15] . Isolated systolic hypertension confers an increased risk for cardiovascular death [33] . There is controversy surrounding whether OA is associated with increased cardiovascular death [34, 35] , but some studies do suggest this [36, 37] , perhaps because OA is a marker of arterial stiffness which would be in keeping with a growing concept that there might be a vascular pathology to OA [38] . Hussain et al. found that those who received incident knee arthroplasties for knee OA had smaller caliber retinal arterioles compared to those who did not receive arthroplasties [39] . Though caliber of retinal arterioles is not a direct measure of vascular pathology at the site of the joint, it is a measure of small arteries. Bearing in mind that using arthroplasty as a marker of OA is suboptimal [40] , this study supports the idea of a vascular pathology to OA. It will be of great interest to better understand differences that exist within specific joint structures, including bone marrow lesions, menisci, synovitis, ligament damage, and attrition in those with and without elevated systolic blood pressure and pulse pressure prior to the development of knee OA. While the OAI has a wealth of data, MRIs, which can ascertain these lesions, at present have only been read on a fraction of the available images. Basic science research on the effect of increased systolic blood pressure and pulse pressure on key joint structures may also be illuminating. There are some limitations to this study. Serum glucose and cholesterol levels were not measured. Therefore, we used diabetic and cholesterol medication uses which were available at each visit, as surrogate assessments for these conditions. Both medication groups were associated with systolic blood pressure and pulse pressure; however, neither was associated with incident ROA. The lack of associations of diabetic and cholesterol medication uses with incident ROA may have resulted from confounding by indication. Therefore, it is still possible that hyperlipidemia [41] [42] [43] and diabetes [44] are risk factors for incident ROA. There is the potential that targeting hyperlipidemia and diabetes, as well as other components of metabolic syndrome, might be helpful in preventing incident OA, which are important questions to address in future research. An additional limitation is that because this is an observational study where participants were initiated on medications in a real-world setting for hypertension to treat elevated blood pressure, we cannot be certain that initiation of antihypertensive agents for the purpose of reducing the risk of knee OA will actually be effective. A double-blinded randomized controlled trial would be needed to address this question. However, it would be prudent to derive a greater understanding of the pathophysiology behind this relationship before embarking on such an intervention study, particularly because the threshold at which SBP seems to confer a greater risk of knee OA is lower than the treatment target for elevated SBP. It is not clear that the riskbenefit ratio is sufficient to recommend this intervention at present.
Given the high prevalence of systemic hypertension and knee OA, the current paucity of practical knee OA preventative strategies, and disease-modifying therapies, the potential implications of our findings are substantial. Though future epidemiologic studies are needed to confirm our findings, this study provides evidence to suggest a new and promising avenue for research on disease modification in knee OA.
Authors' contributions Grace H. Lo had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Dr. Lo conducted and is responsible for the data analyses.
Study concept and design: Lo, McAlindon, Katz, Petersen, and Suarez-Almazor.
Acquisition of data: Lo. Analysis and interpretation of data: Lo, McAlindon, Katz, Driban, Price, Eaton, Petersen, Ballantyne, and Suarez-Almazor.
Drafting of the manuscript: Lo. License statement BI, Grace Lo, the Corresponding Author of this article contained within the original manuscript which includes any diagrams and photographs within and any related or stand alone film submitted (the BContribution^) has the right to grant on behalf of all authors and does grant on behalf of all authors, a license to the BMJ Publishing Group Ltd. and its licensees, to permit this Contribution (if accepted) to be published in the BMJ and any other BMJ Group products and to exploit all subsidiary rights, as set out in our license set out at: http:// www.bmj.com/about-bmj/resources-authors/forms-policies-andchecklists/copyright-open-access-and-permission-reuse.P lease tick one or more boxes as appropriate: ☐I am the sole author of the Contribution. 
